|  |  |
| --- | --- |
| **MEETING SUBJECT:** | **PINTAD 2019 “February” Teleconference** |
| **DATE / TIME:** | **9FEB2019 / 11:00 AM EST** |
| **MINUTES PREPARED BY:** | **Andrea Kolligian** |
| **LOCATION:** | **Teleconference** |

**MEETING SUMMARY**

DISCUSSION POINTS:

|  |  |
| --- | --- |
| **1** | **Welcome** |
| **2** | **Lale Kostakoglu, MD** Professor of Radiology at Mount Sinai Health System, specializing in Nuclear Medicine, lead a discussion of ***“A clinical perspective on the changing landscape in lymphoma criteria”.*** Slides of presentation are also available.   * **Shared examples of challenges with Lugano, Lyric and RECIL criteria.** * **Encouraged the group to start thinking beyond these criteria to more quantitative measures.**   **Comments on presentation:**   * **QIBA has developed FDG-PET profile and protocol that clearly describe standardized imaging procedures to achieve reproducible quantitative endpoints. If followed the reproducibility needed for determination of a minor response in RECIL (10%) should be achieved (Dan Sullivan).** * **There has been a reluctance to use metabolic tumor volume (MTV) and change in clinical trialsas there is insufficient agreement on a standardized approach. Standardization would be greatly beneficial (Lale Kostakoglu).** * **Interest was voiced to explore MTV in available data.** * **It was also suggested that PINTAD could potentially take on benchmarking/ drive an effort harmonizing thresholding approaches in volume determinations** |
| **3** | **Next meeting**  **Friday, 22MAR2019 11:00 am ET** |